Trials / Completed
CompletedNCT00358540
Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide
An Open-label, Dose Ranging Study to Assess the Safety, Efficacy, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (Eltrombopag) Administered to Subjects Receiving Adriamycin and Ifosfamide (AI) Regimen
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study will evaluate the safety and tolerability, optimal biologic dose, and pharmacokinetics of eltrombopag for patients with advanced sarcoma who have a low platelet count and are receiving ADRIAMYCIN and ifosfamide (AI) chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | eltrombopag | Dosing of sarcoma subjects with eltrombopag after treatment with Adriamycin and Ifosfamide. |
Timeline
- Start date
- 2006-06-01
- Primary completion
- 2010-10-22
- Completion
- 2010-10-22
- First posted
- 2006-08-01
- Last updated
- 2017-11-13
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00358540. Inclusion in this directory is not an endorsement.